AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15143088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 15143088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (in subgroup of better prognosis patients, n = 55)
Number of subjects: 385
Study 15143088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup of better prognosis patients, n = 47)
Number of subjects: 385
Study 15143088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 385
Study 11359050 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride slow-releasing glass devices
Number of subjects: 174
Study 9263773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulm sample
Number of subjects: 2
Study 9263773 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Swabia isolate
Number of subjects: 2
Study 2070868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 0
Study 2070868 — intervention group
Group type: COMPARATOR
Intervention: Cervical cap with whole ejaculate or coitus
Number of subjects: 0
Study 6660454 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 80
Study 6660454 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 80
Study 30669521 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Up Milk-Lite (GUMLi)
Number of subjects: 83
Study 30669521 — intervention group
Group type: COMPARATOR
Intervention: Cow's Milk (CM)
Number of subjects: 83
Study 29499060 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC) TB and HIV testing
Number of subjects: 3012
Study 29499060 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care CD4 (PoC CD4)
Number of subjects: 3012
Study 29499060 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care CD4 + Household Isoniazid Preventive Therapy (HH-IPT)
Number of subjects: 3012
Study 26927166 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + WP (20 g whey protein isolate)
Number of subjects: 10
Study 26927166 — intervention group
Group type: COMPARATOR
Intervention: CHO (carbohydrate-rich breakfast without whey protein)
Number of subjects: 10
Study 26927166 — intervention group
Group type: COMPARATOR
Intervention: NB (breakfast omitted)
Number of subjects: 10
Study 26927166 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + WP
Number of subjects: 10
Study 26927166 — intervention group
Group type: COMPARATOR
Intervention: CHO + WP, CHO, NB
Number of subjects: 10
Study 24418941 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tranexamic acid
Number of subjects: 0
Study 24418941 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous tranexamic acid
Number of subjects: 0
Study 24418941 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 0
Study 23059926 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised Motivational Intervention (PMI)
Number of subjects: 218
Study 23059926 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief health information)
Number of subjects: 218
Study 19903626 — intervention group
Group type: EXPERIMENTAL
Intervention: SockIt! Oral Pain Gel applied to dentures
Number of subjects: 44
Study 19903626 — intervention group
Group type: COMPARATOR
Intervention: No topical treatment
Number of subjects: 44
Study 17467426 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-paclitaxel (n = 19)
Number of subjects: 41
Study 17467426 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin-docetaxel (n = 22)
Number of subjects: 41
Study 17467426 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 41
Study 17467426 — intervention group
Group type: EXPERIMENTAL
Intervention: Major response group (persistent N2 disease)
Number of subjects: 41
Study 15965070 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week intensive resistance training regimen in weightlifters
Number of subjects: 36
Study 15965070 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-athletic individuals)
Number of subjects: 36
Study 12090613 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral TV program
Number of subjects: 0
Study 12090613 — intervention group
Group type: COMPARATOR
Intervention: Violent TV program
Number of subjects: 0
Study 12090613 — intervention group
Group type: COMPARATOR
Intervention: Sexually explicit TV program
Number of subjects: 0
Study 9859725 — intervention group
Group type: EXPERIMENTAL
Intervention: Appital
Number of subjects: 59
Study 9859725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7890241 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal alpha 1‐antitrypsin test
Number of subjects: 179
Study 7890241 — intervention group
Group type: COMPARATOR
Intervention: Guaiac occult blood test
Number of subjects: 179
Study 2311145 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural epinephrine (5 micrograms.ml‐1) added to bupivacaine (0.75 per cent)
Number of subjects: 20
Study 2311145 — intervention group
Group type: COMPARATOR
Intervention: Plain epidural bupivacaine (0.75 per cent)
Number of subjects: 20
Study 6770801 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of sustained-release capsules once a day
Number of subjects: 0
Study 6770801 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of capsules twice a day
Number of subjects: 0
Study 6770801 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of tablets four times a day
Number of subjects: 0
Study 6770801 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 0
Study 31429912 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based memory training
Number of subjects: 208
Study 31429912 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based memory training
Number of subjects: 208
Study 31429912 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 208
Study 31393742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component nurse-led lifestyle intervention
Number of subjects: 0
Study 31393742 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28816142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg orally once daily for 14 days with concurrent stereotactic radiosurgery (SRS)
Number of subjects: 17
Study 28816142 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg and 300 mg doses
Number of subjects: 17
Study 28816142 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 17
Study 26347184 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone with levodopa/benserazide (LB)
Number of subjects: 551
Study 26347184 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone with levodopa/carbidopa (LC)
Number of subjects: 551
Study 26347184 — intervention group
Group type: COMPARATOR
Intervention: Entacapone (LB and LC users)
Number of subjects: 551
Study 24235824 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (HBPR) program with aerobic and muscle strength exercises
Number of subjects: 0
Study 24235824 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with instructions for breathing and stretching exercises
Number of subjects: 0
Study 22166188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-type (MED) diet
Number of subjects: 135
Study 22166188 — intervention group
Group type: COMPARATOR
Intervention: Low-fat American Heart Association-type diet
Number of subjects: 135
Study 19358791 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 150 mg/day
Number of subjects: 493
Study 19358791 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 493
Study 19358791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 17536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 15
Study 17536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg)
Number of subjects: 15
Study 17536222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17536222 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast vs Desloratadine
Number of subjects: 15
Study 15028938 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL acetic acid gel, intravaginally twice daily for 7 days
Number of subjects: 44
Study 15028938 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, intravaginally twice daily for 7 days
Number of subjects: 44
Study 11573636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg kg(-1) i.v.
Number of subjects: 80
Study 11573636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11573636 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 2 mg kg(-1) i.v. and Placebo
Number of subjects: 80
Study 9596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac50/misoprostol
Number of subjects: 1824
Study 9596551 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac75/misoprostol
Number of subjects: 1824
Study 7887134 — intervention group
Group type: EXPERIMENTAL
Intervention: NADH, 25 mg, given intravenously once a day for four days, followed by 25 mg NADH intramuscularly after 2 and 4 weeks
Number of subjects: 9
Study 7887134 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (control group)
Number of subjects: 9
Study 3039130 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprocessed bran 5 g three times daily
Number of subjects: 90
Study 3039130 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed bran 2.5 g three times daily
Number of subjects: 90
Study 3039130 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 90
Study 31834410 — intervention group
Group type: COMPARATOR
Intervention: I‐MORE
Number of subjects: 175
Study 31834410 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐MORE+WI
Number of subjects: 175
Study 29510998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (intensive care with cooling of the body to 33.5°C for 72 hours)
Number of subjects: 145
Study 29510998 — intervention group
Group type: COMPARATOR
Intervention: Control (intensive care alone)
Number of subjects: 145
Study 28578607 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (1000 mg daily, given once daily as four 250-mg tablets; prednisone 5 mg daily)
Number of subjects: 1199
Study 26164097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination only
Number of subjects: 267270
Study 26164097 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination and behavioural change
Number of subjects: 267270
Study 26164097 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 267270
Study 23117775 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin
Number of subjects: 14641
Study 23117775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14641
Study 21070998 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp protocol
Number of subjects: 400
Study 21070998 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 400
Study 18172412 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle strength training (IMT) for 10 weeks
Number of subjects: 46
Study 18172412 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment control group
Number of subjects: 46
Study 15879021 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB/C
Number of subjects: 0
Study 15879021 — intervention group
Group type: COMPARATOR
Intervention: MenBvac
Number of subjects: 0
Study 15879021 — intervention group
Group type: COMPARATOR
Intervention: Menjugate
Number of subjects: 0
Study 15879021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11932859 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen peas
Number of subjects: 20
Study 11932859 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible frozen gel pack
Number of subjects: 20
Study 11932859 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 9800740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg per day)
Number of subjects: 496
Study 9800740 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 496
Study 8617576 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate
Number of subjects: 55
Study 8617576 — intervention group
Group type: EXPERIMENTAL
Intervention: Amonafide
Number of subjects: 55
Study 8617576 — intervention group
Group type: EXPERIMENTAL
Intervention: Teniposide
Number of subjects: 55
Study 2548551 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (4 mg)
Number of subjects: 0
Study 2548551 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 0
Study 2548551 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 0
Study 2548551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 132566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide (30 mg or more)
Number of subjects: 0
Study 132566 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanthelinbromide
Number of subjects: 0
Study 132566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropiumbromide + Oxacepam
Number of subjects: 0
Study 132566 — intervention group
Group type: COMPARATOR
Intervention: Oxacepam
Number of subjects: 0
Study 31322583 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude of motor evoked potentials of the extensor digitorum communis (EDC) muscle
Number of subjects: 18
Study 31322583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to voluntarily extend the fingers
Number of subjects: 18
Study 31322583 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP amplitudes of biceps brachii and adductor digiti minimi muscles
Number of subjects: 18
Study 29699723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine racemate
Number of subjects: 80
Study 29699723 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 26937913 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 187
Study 26937913 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional care)
Number of subjects: 187
Study 24509214 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1442
Study 24509214 — intervention group
Group type: COMPARATOR
Intervention: Past smokers
Number of subjects: 1442
Study 24509214 — intervention group
Group type: COMPARATOR
Intervention: Total cohort of patients
Number of subjects: 1442
Study 24509214 — intervention group
Group type: COMPARATOR
Intervention: Patients with ischemic and nonischemic cardiomyopathy
Number of subjects: 1442
Study 21316256 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure of donor site (group 1)
Number of subjects: 15
Study 21316256 — intervention group
Group type: COMPARATOR
Intervention: Granulation of donor site (group 2)
Number of subjects: 15
Study 21316256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 15
Study 20156055 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm I: Isoniazid, rifampicin, and pyrazinamide simultaneously at full dosage from day 1
Number of subjects: 175
Study 20156055 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm II: Drugs administered according to American Thoracic Society guidelines
Number of subjects: 175
Study 20156055 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm III: Drugs administered according to British Thoracic Society guidelines
Number of subjects: 175
Study 18030209 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.25 mg/kg subcutaneously each week)
Number of subjects: 24
Study 15682323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 of 30%) during Moderate1
Number of subjects: 9
Study 15682323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 of 30%) during Moderate2
Number of subjects: 9
Study 15682323 — intervention group
Group type: COMPARATOR
Intervention: Normoxia during Moderate1
Number of subjects: 9
Study 15682323 — intervention group
Group type: COMPARATOR
Intervention: Normoxia during Moderate2
Number of subjects: 9
Study 15682323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 of 30%)
Number of subjects: 9
Study 10222855 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching video for discharge preparatory teaching
Number of subjects: 59
Study 10222855 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching
Number of subjects: 59
Study 7884421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (cyclophosphamide 7.2 g/m2, carmustine 300 mg/m2 or 600 mg/m2, etoposide 2,400 mg/m2) followed by allogeneic bone marrow transplantation (allo BMT)
Number of subjects: 56
Study 7884421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (carmustine 600 mg/m2)
Number of subjects: 56
Study 7884421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy regimen (carmustine 300 mg/m2)
Number of subjects: 56
Study 7884421 — intervention group
Group type: EXPERIMENTAL
Intervention: Allo BMT following high-dose CBV regimen
Number of subjects: 56
Study 7884421 — intervention group
Group type: EXPERIMENTAL
Intervention: Allo BMT for advanced disease
Number of subjects: 56
Study 7884421 — intervention group
Group type: EXPERIMENTAL
Intervention: Allo BMT
Number of subjects: 56
Study 2102750 — intervention group
Group type: COMPARATOR
Intervention: Sustained-action nifedipine (NF)
Number of subjects: 72
Study 2102750 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL)
Number of subjects: 72
Study 638577 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 10 microgram/min
Number of subjects: 62
Study 638577 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline 1 mg/min
Number of subjects: 62
Study 31809413 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea
Number of subjects: 12
Study 31809413 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 31809413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31744484 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer evaluation in pharmacodynamics items (PE-PD)
Number of subjects: 72
Study 31744484 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer evaluation in pharmacokinetics items (PE-PK)
Number of subjects: 72
Study 31744484 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' marks for oral presentation (PE-PD)
Number of subjects: 72
Study 31744484 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' marks for oral presentation (PE-PK)
Number of subjects: 72
Study 31744484 — intervention group
Group type: EXPERIMENTAL
Intervention: Final examination marks (PE-PD)
Number of subjects: 72
Study 31744484 — intervention group
Group type: EXPERIMENTAL
Intervention: Final examination marks (PE-PK)
Number of subjects: 72
Study 28343757 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF‐M HP
Number of subjects: 112
Study 28343757 — intervention group
Group type: COMPARATOR
Intervention: Menopur
Number of subjects: 112
Study 25645122 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care (COPD-Home)
Number of subjects: 172
Study 25645122 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study 23468158 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking slowly (slower)
Number of subjects: 48
Study 23468158 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with cueing at the BEFORE pace (metronome)
Number of subjects: 48
Study 23468158 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking without cueing at the BEFORE pace (normal)
Number of subjects: 48
Study 23468158 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking fast (faster)
Number of subjects: 48
Study 20961772 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic talc poudrage (TTP)
Number of subjects: 42
Study 20961772 — intervention group
Group type: COMPARATOR
Intervention: Povidone‐iodine pleurodesis (PIP)
Number of subjects: 42
Study 20961772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TTP and PIP)
Number of subjects: 42
Study 20146877 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day (bid)
Number of subjects: 1598
Study 20146877 — intervention group
Group type: COMPARATOR
Intervention: Tramadol HCl 50 mg four times a day (qid)
Number of subjects: 1598
Study 20146877 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg bid
Number of subjects: 1598
Study 17579709 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision protocol for identifying obesity risk
Number of subjects: 5778
Study 17579709 — intervention group
Group type: COMPARATOR
Intervention: Non-selected peers
Number of subjects: 5778
Study 16321614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin B(2) receptor antagonist HOE 140 (100 mug/kg)
Number of subjects: 16
Study 16321614 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 16
Study 12029261 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII) administration
Number of subjects: 0
Study 12029261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12029261 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (concomitant use)
Number of subjects: 0
Study 9534634 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 20
Study 9534634 — intervention group
Group type: COMPARATOR
Intervention: Different definitions of hypotension and baseline measurements
Number of subjects: 20
Study 8042462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pad with traditional cellulose absorbent core
Number of subjects: 0
Study 8042462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pad containing cellulose and absorbent gelling material
Number of subjects: 0
Study 8042462 — intervention group
Group type: COMPARATOR
Intervention: Non-pad control period
Number of subjects: 0
Study 2639195 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthrinse
Number of subjects: 40
Study 2639195 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 40